- Home
- USGO vs VERU Comparison
USGO vs VERU Comparison
Compare USGO & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USGO
- VERU
- Stock Information
- Founded
- USGO 2015
- VERU 1971
- Country
- USGO United States
- VERU United States
- Employees
- USGO N/A
- VERU N/A
- Industry
- USGO Precious Metals
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- USGO Basic Materials
- VERU Health Care
- Exchange
- USGO Nasdaq
- VERU Nasdaq
- Market Cap
- USGO 117.3M
- VERU 94.5M
- IPO Year
- USGO 2023
- VERU 1990
- Fundamental
- Price
- USGO $8.25
- VERU $0.60
- Analyst Decision
- USGO Strong Buy
- VERU Strong Buy
- Analyst Count
- USGO 1
- VERU 2
- Target Price
- USGO $26.50
- VERU $4.00
- AVG Volume (30 Days)
- USGO 37.0K
- VERU 2.8M
- Earning Date
- USGO 08-12-2025
- VERU 08-07-2025
- Dividend Yield
- USGO N/A
- VERU N/A
- EPS Growth
- USGO N/A
- VERU N/A
- EPS
- USGO N/A
- VERU N/A
- Revenue
- USGO N/A
- VERU $16,886,419.00
- Revenue This Year
- USGO N/A
- VERU N/A
- Revenue Next Year
- USGO N/A
- VERU N/A
- P/E Ratio
- USGO N/A
- VERU N/A
- Revenue Growth
- USGO N/A
- VERU 134.43
- 52 Week Low
- USGO $5.00
- VERU $0.45
- 52 Week High
- USGO $14.46
- VERU $1.42
- Technical
- Relative Strength Index (RSI)
- USGO 39.64
- VERU 51.69
- Support Level
- USGO $8.09
- VERU $0.57
- Resistance Level
- USGO $8.78
- VERU $0.73
- Average True Range (ATR)
- USGO 0.43
- VERU 0.05
- MACD
- USGO -0.11
- VERU -0.01
- Stochastic Oscillator
- USGO 27.15
- VERU 29.41
About USGO U.S. GoldMining Inc. Common stock
US Goldmining Inc is a mineral exploration and development company. It is focused on the exploration and development of a project located in Alaska, USA. The company's sole property is Whistler Project which is a gold-copper exploration project located in the Yentna Mining District, approximately 170 km northwest of Anchorage, Alaska.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.